Literature DB >> 3535866

Scl 70 antibody--a specific marker of systemic sclerosis.

M Jarzabek-Chorzelska, M Blaszczyk, S Jablonska, T Chorzelski, V Kumar, E H Beutner.   

Abstract

Scl 70 antibodies were tested for in 107 patients with systemic sclerosis: 68 with acrosclerosis and 39 with diffuse scleroderma. Anticentromere antibodies (ACA) and other antinuclear antibodies (ANA) were tested for by indirect immunofluorescence on HEp-2 cells. Positive results for Scl 70 antibodies were obtained in 77% of cases of diffuse scleroderma and 44% of acrosclerosis. ACA and Scl 70 antibodies were found to be mutually exclusive. If acrosclerosis cases positive for anticentromere antibodies are excluded, the percentage of acrosclerosis cases positive for Scl 70 was 63%. ACA were found to be a marker of a benign, abortive subset of acrosclerosis with almost no cutaneous involvement (CREST), whereas Scl 70 did not discriminate between acrosclerosis and diffuse scleroderma. On HEp-2 cells Scl 70 positive sera gave a characteristic, fine speckled, almost homogeneous nuclear staining pattern.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535866     DOI: 10.1111/j.1365-2133.1986.tb06233.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  18 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; Z Kolacinska-Strasz; T Chorzelski; S Jabłońska; G G Maul
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

4.  IMPACT OF AGE AND AUTOANTIBODY STATUS ON THE GENE EXPRESSION OF SCLERODERMA FIBROBLASTS IN RESPONSE TO SILICA STIMULATION.

Authors:  Y Yang; P Wei; X J Guo; D Zhou; W Z Zhang; S Assassi; X D Zhou
Journal:  Eur J Inflamm       Date:  2013-09       Impact factor: 0.466

5.  Lymphocytotoxic autoantibodies in progressive systemic sclerosis.

Authors:  K Herrmann; J Schaller; U F Haustein; C Baldauf; S Kiessig
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

6.  Anti-fibrillarin autoantibodies in mercury-treated mice.

Authors:  P Hultman; S Eneström; K M Pollard; E M Tan
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

7.  A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis.

Authors:  R Verheijen; F Van den Hoogen; R Beijer; A Richter; E Penner; W J Habets; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

8.  HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans.

Authors:  Xiaodong Zhou; Jong Eun Lee; Frank C Arnett; Momiao Xiong; Min Young Park; Yeon Kyeong Yoo; Eun Soon Shin; John D Reveille; Maureen D Mayes; Jin Hyun Kim; Ran Song; Ji Yong Choi; Ji Ah Park; Yun Jong Lee; Eun Young Lee; Yeong Wook Song; Eun Bong Lee
Journal:  Arthritis Rheum       Date:  2009-12

9.  Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods.

Authors:  S Majewski; M Błaszczyk; S Jabłonska; L Rudnicka; M Waşik; A Skiendzielewska; B Makieła
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

10.  Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations.

Authors:  M Vayssairat; N Baudot; N Abuaf; C Johanet
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.